Retension Pharmaceuticals (RTSN) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical developer focused on hypertension and other cardiovascular diseases; RTN-001 is its sole product candidate, a once-daily oral PDE-5 inhibitor designed to enhance nitric oxide-cGMP signaling.

• RTN-001 is engineered for higher bioavailability and distribution into central vascular smooth muscle than first-generation PDE-5 inhibitors; development targets uncontrolled and resistant hypertension.

• Development relies on third-party CROs and manufacturers; no internal manufacturing facilities are planned for the foreseeable future.

• Strategy includes advancing RTN-001 in hypertension, exploring cardiovascular and renal indications and combination treatments, and evaluating partnerships and selective pipeline expansion.

Financial performance and metrics

• FY25 restated net loss $6.3M vs $1.9M in FY24; H1 2026 net loss $7.5M vs $1.9M in H1 2025.

• H1 2026 R&D expense $6.2M vs $1.2M YoY; G&A $1.6M vs $0.9M. Phase 2b CRO costs drove most of the R&D increase.

• Cash and cash equivalents were $13.5M at June 30, 2026, down from $18.9M at December 31, 2025; accumulated deficit was $15.8M.

• No product revenue; recurring losses, negative operating cash flows and the independent auditor's going-concern paragraph indicate substantial doubt about funding operations for 12 months after interim statements were issued.

Use of proceeds and capital allocation

• Net proceeds plus existing cash are intended to complete the RTN-001 Phase 2b trial and prepare for, support and advance the planned Phase 3 trial; remaining proceeds go to general corporate purposes and operating expenses.

• Proceeds may also fund complementary acquisitions or strategic investments; management retains broad discretion over allocation.

• Proceeds and existing cash are expected to complete Phase 2b, but not Phase 3 or later development, regulatory approval and commercialization; further capital will be required.